Announced today by Robert Pryke, PFD Capital Partners LLC, Director and Fund Manager for PFD Special Medical Receivables Hybrid (SMH) 3002, that Regeneration Biomedical, Inc. (RBI)—a clinical-stage biotechnology company advancing stem cell-based therapies for neurodegenerative diseases—will be included in its upcoming PFDSMH3002.